

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 October 2008 (09.10.2008)

PCT

(10) International Publication Number
WO 2008/119160 A1

(51) International Patent Classification:

A61K 38/21 (2006.01) A61K 9/107 (2006.01)
A61K 31/198 (2006.01) A61K 9/127 (2006.01)
A61K 9/06 (2006.01)

(21) International Application Number:

PCT/CA2008/000563

(22) International Filing Date: 27 March 2008 (27.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/909,324 30 March 2007 (30.03.2007) US

(71) Applicant (for all designated States except US): PHARMADERM LABORATORIES LTD. [CA/CA];

#301-111 Research Drive, Innovation Place Research Park, Saskatoon, Saskatchewan S7N 3R2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FOLDVARI, Marianna [CA/CA]; 2231 Hidden Valley Crescent, Kitchener,

Ontario N2C 2R2 (CA). KUMAR, Praveen [CA/CA]; 111 Weyakwin Drive, Saskatoon, Saskatchewan S7J 4N3 (CA). DOCHERTY, John, M. [CA/CA]; 12 Barberry Crescent, Richmond Hill, Ontario L4E 4S4 (CA).

(74) Agents: ERRATT, Judy, A. et al.; Gowling Lafleur Henderson LLP, 160 Elgin Street, suite 2600, Ottawa, Ontario K1P 1C3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY




Fig. 4

(57) Abstract: A biphasic lipid vesicle composition for treating cervical dysplasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1- 20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.

WO 2008/119160 A1



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

BIPHASIC LIPID-VESICLE COMPOSITION AND METHOD FOR
TREATING CERVICAL DYSPLASIA BY INTRAVAGINAL DELIVERY

Field of the Invention

[0001] The present invention relates a biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery.

Background of the Invention

[0002] Of the estimated 55 million Pap smears performed each year in the United States, more than 5% are reported as abnormal (ALTS study 2003). An estimated 800,000 women each year present with low-grade squamous intraepithelial lesions (LSIL) (Jones, BA, Davey DD. Quality management in gynaecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000;124(5):672-81).

[0003] These lesions will either progress with time to CIN 2-3 or invasive cancer, especially in women that present with the high-risk HPV-subtype, or regress with time in the absence of treatment. Of women diagnosed with LSIL, 25% will progress to cervical intraepithelial neoplasia (CIN) grade 2 or 3, 22-32% will have persistent CIN 1 and approximately 50%-70% will experience spontaneous regression of LSIL within 2 years (ALTS group 2003, Östör AG Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol Pathol 1993;12:186-92). Approximately 75% will experience spontaneous regression within 5 years.

[0004] The cytologic LSIL definition of the Bethesda System is different from the Munich classification system used in Germany and throughout the EU. LSIL corresponds to condyloma or CIN 1 in the Bethesda System. In the Munich classification these findings are represented in the Pap groups II W-III D. However, it should be noted that in group III D also patients with colposcopic diagnosis of CIN 2 (moderate dysplasia) are included.

[0005] At present, there is no immediate therapy available for women with HPV presenting with LSIL. Once a low-grade abnormal Pap smear has been detected, the patient and the clinician are left with the choice of either repeating

it one or more times, or proceeding to colposcopy. Colposcopy is often accompanied by biopsy. Based on the findings of the colposcopy and biopsy, treatment options include conization, cryotherapy or laser treatment. Women who have undergone such treatment options may carry an increased risk of abortion and premature labor.

[0006] There are a number of clinical trials that have been published that describe interferons to be effective against a variety of HPV cervical infections. Studies on the use of interferons for the treatment of cervical intraepithelial neoplasia report cure rates between 0 – 100%. These variations most likely reflect differences in dosage, duration of treatment, mode of application, study design, severity of disease, and measures of efficacy.

[0007] In an open study, Penna *et al.* (1994) (Penna C, Fallan MG, Gordigiani R *et al.*, Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection, *Tumori* 1994; 80:146-150) reported 80% lesion regression and 51% reversion of HPV type 16/18 to normal following daily intra-perilesionally application into the cervix in women with CIN associated with HPV infection of 3 MIU of IFN beta for 3 weeks. Similarly, in an open pilot study, Katesmark *et al.* (1999) (Katesmark M., Coulter Smith S., Reynolds K., Lawton F. A pilot study of the efficacy and tolerability of intralesional recombinant human beta interferons in cervical intraepithelial neoplasia. *Ann Acad Singapore* 1999; 28(6):775-7) showed a 73% histology complete response rate of CIN when IFN was injected into the transformation zone.

[0008] Schneider *et al.* (1995) (Schneider A, Grubert T, Kirchmayr R, Wagner D, Papendick U, Schlunck G. Efficacy trial of topically administered Interferon gamma-1b gel in comparison to laser treatment in cervical intraepithelial neoplasia. *Arch Gynecol Obstet* 1995; 256:75-83) reported a 42% complete response, 42% partial response following IFN-gamma 1b gel therapy in women with CIN. In this study, patients with CIN II responded better compared with CIN III. It is also of interest to note that smokers showed a significantly lower cure rate when compared to non-smokers.

[0009] Zarccone *et al.* (1995) (Zarccone R., Bellini P., Cardone G., Cardone A. Treatment of cervix condylomata with alpha-IFN leucocytar. *Clin Exp Obst Gyn*

1995;22(4):326-9) have reported success in a small, 12-patient study with combined intramuscular and topical alpha-IFN therapy in the treatment of CIN I and II, in HPV+ women. The administration of intramuscular doses of up to 3 MIU daily IFN for 3 weeks, combined with intravaginal application of an unspecified dose of IFN cream during the last two weeks of treatment, resulted in a complete response in 7 patients, partial response in 4 patients, and no response in 1 patient.

[0010] Syed *et al.* (1998) (Syed TA, Ahmadpour A. Human leukocyte derived interferon-a in hydrophilic gel for the treatment of intravaginal warts in women: a placebo-controlled, double-blind study. *Intl J STD and AIDS* 1998;9:769-772) demonstrated that 16 MIU daily dose of a hydrophilic gel of interferon alpha administered intravaginally for 5 consecutive days per week over a 4-week treatment period was significantly more effective than placebo at curing vaginal warts. While these studies show that interferon therapy is effective in treating CIN associated HPV infections as measured by colposcopy confirmed by cytological and histological examination of random biopsies, none of these studies examine the HPV status post therapy.

[0011] Based on various limitations in these studies, a non-invasive therapy that could reverse the abnormal cytology during the early stages of the disease process and diminish or eradicate HPV presence would provide a significant benefit to the healthcare system and the physical and emotional well-being of many young women.

Summary of the Invention

[0012] In one aspect, the invention includes a biphasic lipid vesicle composition for treating cervical dysplasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and methionine, the composition having an interferon-alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition and between 0.01 to 0.5 weight percent methionine.

[0013] The composition, which may be in a cream form, contains in particular embodiments, interferon alpha-2b at a specific activity between 1 and 3 MIU

human interferon alpha-2b per gram composition and between 0.01 to 0.5 weight percent L-methionine

[0014] In another aspect, the invention includes a method of treating cervical dysplasia in the subject by administering the above composition intravaginally to the subject, at a dose of between 1-20 MIU interferon alpha-2b, and repeating the dosing at least 3 days/week, for a period of at least 4 weeks.

[0015] These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying drawings.

Brief Description of the Drawings

[0016] FIG. 1 is a scanned image of multilamellar lipid vesicles in the composition of the invention, prepared using an anhydrous plastic proliposome gel method;

[0017] FIG. 2A is a scanned image of multilamellar liposomes prepared using an "anhydrous plastic proliposome-gel" (`melt` or `fusion`) method.

[0018] FIG. 2B is a scanned image of multilamellar liposomes the same composition as in 2A, but prepared by a solvent evaporation method.

[0019] FIG. 3 is a schematic sectional view of a biphasic MLV with a central aqueous emulsion core, and

[0020] FIG. 4 is an enlarged portion of the MLV of FIG. 3.

Detailed Description of the Invention

I. Biphasic Liposome Composition and method of its preparation

[0021] The invention relates to a lipid-bilayer or liposome or lipid vesicle composition for use in delivering an interferon, e.g., interferon alpha-2b by transmucosal delivery, e.g., by intravaginal administration, particularly in the treatment of cervical dysplasia.

[0022] A preferred method of preparing a multilamellar lipid vesicle of the invention is as follows. An oil and a consistency enhancer are admixed. Separately, water and a surfactant are admixed. A water-soluble antimicrobial agent, for example methyl paraben or propylparaben, a buffering agent, such as phosphates, and a chelating agent, such as EDTA, can also be dissolved in the

water. These are heated gently, say to about 70°C., and then admixed and homogenized with the oil and consistency enhancer. This results in formation of an emulsion with water as the continuous phase and the oil and consistency enhancer as the dispersed phase. It is desirable that the oil droplets shall be less than about 1 μm , especially less than about 0.5 μm , in diameter and if necessary the emulsion can be subjected to additional shear or to sonification to reduce the size of the droplets.

[0023] Separately there is prepared an anhydrous proliposome gel by admixing phospholipid, glycolipid and/or ceramide and a pharmaceutically acceptable hydrophilic solvent, *e.g.*, propylene glycol, and heating them to form a melt. In the melt there may also be incorporated a material to enhance the strength of the lipid bilayers, for example cholesterol, a material to enhance penetration, for example monolauryllysine and a material to impart a charge to the lipid bilayers, for example stearic acid. A small amount of an antioxidant, for example ascorbyl palmitate, butylated hydroxytoluene or butylated hydroxyanisole can be incorporated in the melt. The aqueous emulsion is added to the melt and the various components are subjected to agitation which results in formation of the desired multilamellar lipid vesicles having in the central core compartment an aqueous emulsion containing the oil and consistency enhancer as the dispersed phase.

[0024] A water-soluble biologically active material, and in particular, human interferon alpha-2b can be incorporated in solution in the aqueous phase of the emulsion, as discussed below. The interferon alpha-2b is incorporated into the aqueous phase to form a final composition having a specific activity of between 1-10 MIU per gram composition. The composition is also formulated to contain between 0.01 to 0.5 weight percent of L-methionine, *e.g.*, 0.01-0.2 weight percent L-methionine, and this component may also be incorporated into the aqueous phase at a concentration effective to give the desired concentration in the final composition, and a chelating agent such as EDTA or an antioxidant such as L-methionine and/or a protein stabilizer such as glycine.

A. Formation of an anhydrous plastic proliposome gel

[0025] A liposome-forming component and other necessary excipients are melted with a pharmaceutically acceptable hydrophilic solvent, such as propylene glycol.

[0026] The expression "liposome-forming component" designates the substance or substances used as major component of the lipid bilayers. Typical liposome-forming components include glycolipids, lecithins, phospholipids, ceramides or mixtures thereof which are used as a primary ingredient in the formation of the lipid bilayer. However, other natural and synthetic compounds having the required amphipatic character can be incorporated with the phospholipid, glycolipid or ceramide, replacing some of these expensive materials, provided that the essential character of the lipid bilayers is not adversely affected. The choice of the appropriate materials is within the knowledge of the person skilled in the art. Examples include phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid and the cerebrosides, ether lipids and phytanols.

[0027] The liposomal formulations of the present invention preferably contain saturated and/or unsaturated phospholipids, more preferably phosphatidylcholine, lysophosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, glycolipids and ceramides. The phospholipids are preferably in combination with a penetration enhancing agent such as monolauroyllysine, dipalmitoyllysine or methyl salicylate to achieve predominantly transdermal delivery potential.

[0028] A "fatty substance" can be used to enhance the strength of the lipid bilayers. Examples of useful fatty substances include steroids such as cholesterol, coprostanol, cholestanol and cholestane and long chain fatty acids (C_{16} to C_{22}), especially saturated ones such as stearic acid. In addition to enhancing strength of the lipid bilayer, acids impart a negative charge. Saturated or unsaturated acids can be used. Other fatty substances that can be used include C_{16} to C_{22} fatty amines, fatty acylated proteins, fatty acylated peptides, fatty acylated PEG and derivatives. These fatty substances are incorporated with the abovementioned liposome-forming components and

improve physical stability and appearance of the product.

[0029] The hydrophilic solvent is used as a plasticizer of the liposome-forming component and an aid to prepare a uniform melt. Examples of hydrophilic solvents include but are not restricted to propylene glycol, glycerol, polyethylene glycol having a molecular weight ranging between 300 and 8000, ethanol, and mixtures thereof. The resulting melt can be described as being an anhydrous plastic proliposome gel. This anhydrous plastic proliposome gel contains all the lipid phase ingredients and can be prepared and stored in advance in large quantities. It is a semisolid material with a homogenous consistency.

B. Formation of the multilamellar lipid vesicles

[0030] Hydrophilic ingredients such as penetration enhancers, preservatives and the like, are prepared separately as an aqueous solution, which forms the continuous phase of an emulsion. This is added to the lipid phase melt, previously heated to the appropriate melting temperature that can range from 40°C. to 80°C., and vigorously mixed by any given technique which allows the achievement of the desired product size. Examples of mixing techniques include vortexing or propeller mixing. At this stage, it is also possible to incorporate (dissolve) solid biologically active agents that will be entrapped within the lipid bilayers.

[0031] This procedure is suitable for the preparation of various amounts of topical liposomal product. If vortex mixing is used as the agitation, up to about 20 g of the product can be prepared. If a laboratory scale propeller mixer is used, up to about 2 Kg to 10 Kg of the product can be made. This formulation procedure can also be adapted for large scale manufacturing. Hence, the propeller mixing technique can be directly scaled up by geometrically increasing the size of the vessel and the diameter of the propeller mixer. However, as the vessel size increases, the preferred set up would be a combination mixer *i.e* a high intensity mixer with propeller mixer and a scraped surface agitator. The aqueous phase can either be pumped from tank A to tank B containing the anhydrous plastic proliposome gel or the aqueous phase can be mixed with the emulsion prior to adding to Tank B at the required temperature and mixed. This procedure is suitable for the production of any topical liposomal product on a large scale.

[0032] Liposomal compositions can be prepared with the multilamellar lipid vesicles of the present invention by using appropriate pharmaceutical additives. For example, it might be required to add viscosity increasing agents to the final liposome preparation. The addition of other pharmaceutically acceptable compounds is within the purview of the person skilled in the art.

C. Characteristics of the final multilamellar lipid vesicle product

[0033] A schematic representation of a multilamellar lipid vesicle prepared in accordance with the process described above is shown at FIG. 3. The multilamellar lipid vesicle, generally designated by reference numeral 2, is made of a series of spaced apart lipid bilayers 4, 6 and 8 which define a series of peripheral aqueous solution compartments 3 and 5. The smallest lipid bilayer 7 defines in its center a central core compartment 9. Although only 6 lipid bilayers are shown, it should be appreciated that the figure is simplified and schematic and in fact many more than 6 lipid bilayers are present.

[0034] FIG. 4 is an enlargement of the vesicle of FIG. 3 showing in more detail the central core compartment and parts of some of the lipid bilayers. The central core compartment 9 is occupied by an aqueous emulsion composed of water 10 as continuous phase and lipophilic droplets or fine solid particles 11 as dispersed phase. The lipophilic droplets or fine solid particles are surrounded by a layer of surfactant molecules 12, the hydrophilic portions 13 of each surfactant molecule extending into the aqueous phase and the hydrophobic portions being at the surface of the oil droplets.

[0035] Surrounding the core compartment is the innermost lipid bilayer 15. The lipid bilayer is composed of two layers of lipid molecules 16. Each lipid molecule 16 in a layer is oriented substantially parallel to adjacent lipid bilayers, and two layers that form a bilayer have the polar ends 17 of their molecules exposed to the aqueous phase and the non-polar ends 18 adjacent to each other. Between the innermost lipid bilayer 15 and the next innermost lipid bilayer 19 is a peripheral compartment 20 that is filled either with water or with the aqueous emulsion. As shown, surfactant surrounded lipophilic droplets or particles 11 can be present in the peripheral compartment 20.

[0036] Surrounding the peripheral compartment 20 is the next innermost lipid bilayer 19, which is in turn surrounded by a further peripheral compartment and a

further lipid bilayer.

[0037] It will be appreciated that biologically active ingredient, *e.g.*, interferon alpha-2b, and the L-methionine component will be present in the water of the aqueous emulsion in the central core compartment 9 and in the peripheral compartments 20. Biologically active ingredients that are lipophilic, such as consistency enhancers or uptake enhancers, can be present in the dispersed phase of the emulsion in the central compartment 9 and in the peripheral compartments 20. They can also be present in the interior of the lipid bilayers as shown at 21. The biologically active ingredient can constitute the lipophilic droplets 21, or the biologically active ingredient can be dissolved in a lipophilic solvent that forms droplets 21. Thus the invention permits the topical application of biologically active ingredients that are water-soluble or water-insoluble.

[0038] The composition is preferably formed under conditions in which at least about 30 weight percent, and preferably between about 40 and 70 weight percent of these aqueous components is present in liposome entrapped form, as opposed to being carried in the extra-vesicular bulk phase of the composition. These levels of entrapment can be achieved by various known strategies, *e.g.*, forming the liposomes by a reverse-phase evaporation method and/or encapsulating the aqueous phase material at a high concentration of liposome-forming lipids, thus minimizing the amount of bulk aqueous phase.

[0039] FIG. 1 is a scanned image, magnified 440X of vesicles made for use as a topical lotion. This product displayed the consistency of a lotion or semi-solid cream. Inspection of the scanned image reveals multilamellar structures with uniform size distribution. These have displayed physical stability for extended periods of time of more than one year.

[0040] In order to demonstrate the difference in properties observed in the liposome population produced in accordance with the preferred method of the present invention, comparative tests were conducted between two liposome compositions prepared from the same ingredients but using in one case the solvent evaporation method and in the other case the preferred anhydrous plastic proliposome gel method. FIG. 2A is a scanned image of the liposome population prepared using the anhydrous proliposome gel (`melt` or `fusion`) method and FIG. 2B is a scanned image of the liposome population prepared

using the solvent evaporation method. As can be seen, the liposome population obtained using the anhydrous plastic proliposome gel method has a liposome size distribution which is substantially more uniform than that obtained using the solvent evaporation method. Also, minimal amounts of aggregated or fused liposomes are formed when using the anhydrous plastic proliposome gel method, whereas large aggregates can be observed in the liposome population obtained using the solvent evaporation method.

[0041] In some embodiments of the invention the lipophilic substance is an oil or solid/semisolid lipophilic consistency enhancer which can be encapsulated into liposomes. As solid or semisolid lipophilic consistency enhancers there are mentioned fatty alcohols, waxes, fatty alcohol fatty acid esters, glyceride esters, white petrolatum and mixtures thereof. Examples of oils which have successfully been encapsulated into liposomes pentaerythritol tetracaprylate/caprate, pentaerythritol tetraisostearate, cetearyl octanoate and canola oil, jojoba oil, peanut oil, rice bran oil, cottonseed oil, sunflower oil, corn oil, walnut oil, avocado oil, peru balsam, clove oil and eugenol. Plant extracts based on oil have also been successfully incorporated into liposomes. Solid/semi solid lipophilic consistency enhancer ingredients can be selected from waxes, fatty alcohols, fatty acid esters, glyceryl stearate, petrolatum or combinations thereof. Specific examples of preferred consistency enhancers include beeswax, glyceryl tribehenate, glyceryl stearate, stearyl heptanoate, stearyl palmitate, cetyl alcohol, stearyl alcohol, myristyl myristate, behenyl erucate and cetyl palmitate.

[0042] The viscosity of a composition of vesicles in accordance with the invention and containing a consistency enhancer is greater than the viscosity of corresponding vesicles that do not include a consistency enhancer but are otherwise identical. By varying the amount of consistency enhancer it is possible to achieve virtually any required viscosity, from a relatively mobile liquid, to a "lotion", to "creamy" to "thick cream". Determination of amounts of consistency enhancer to achieve a particular viscosity of the composition can be determined by routine experiment.

[0043] The surfactant used to coat the oil droplet or the solid/semisolid lipophilic consistency enhancer ingredients is important for the successful encapsulation of a lipophilic core into multilamellar lipid vesicles. About 30

different types of surfactants were screened and primary cationic emulsifiers were found to give the most acceptable results. The most preferred surfactant is benzalkonium chloride. Nonionic or amphoteric surfactants can also be used, such as naturally derived emulsifiers: PEG-60 almond glycerides, avocado oil diethanolamine, ethoxylated jojoba oil (PEG-40 Jojoba acid and PEG-40 Jojoba alcohol); polyoxyethylene derivatives: polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monostearate; lanolin derivatives: polychol 20 (Laneth 20), polychol 40 (laneth 40); neutral phosphate esters: PPG-cetyl ether phosphate, DEA oleth-3 phosphate. It is also possible to use anionic surfactants such as acylglutamates: TEA-cocoyl glutamate, sodium lauroyl glutamate, sodium hydrogenated tallow glutamate and sodium cocoyl glutamate. It is desirable that the surfactant has a high critical micellar concentration (CMC).

[0044] When preparing the lipophilic substance-in-water emulsion, the hydrophilic ingredients and surfactants are all incorporated in water. Once the water phase of the emulsion has been prepared, the oil and/or solid/semisolid lipophilic ingredients are added to the water in a homogenizer for a period of time ranging from 5 to 30 minutes to obtain relatively small droplet size. Preferred droplet size ranges from 0.1um to 1 um, most preferably below about 0.5 um. The lipid phase melt is then heated and the lipophilic substance-in-water emulsion is added and vigorously mixed by either vortexing or propeller mixing depending on the product size.

[0045] The formulation procedure described above can be easily adopted for large scale manufacturing. The propeller mixing approach can be directly scaled up by geometrically increasing the size of the vessel and the diameter of the propeller mixer. However, as the vessel size increases, a preferred set up might be a combination mixer such as a high intensity mixer with propeller mixer and a scraped surface agitator. In a large scale operation, the lipophilic substance-in-water emulsion can be pumped from a first tank into a second tank containing the anhydrous plastic proliposome gel at the required temperature and mixed.

[0046] With the multilamellar lipid vesicle of the present invention, oil droplets containing solubilized lipophilic biologically active compounds or oily plant extracts can be delivered through liposome encapsulation. Furthermore, the possibility of multicompartment encapsulation provides drug release over

extended periods of time. Also, encapsulation of lipophilic solid/semisolid consistency enhancers into the central lipophilic core compartment provides enhanced viscosity to the final liposome composition. In this case, the addition of viscosity-increasing agents in the final liposome preparation can be avoided.

[0047] Overall, the preparation of multilamellar lipid vesicles with a central emulsion core component provides a physically stable, uniform liposome composition. The composition has a viscosity that is suitable for topical administration and can be easily manufactured on a large scale.

D. Exemplary IFN-alpha-2b cream formulation for intravaginal use

[0048] Table 1 gives the components in one exemplary lipid-bilayer composition formed in accordance with the invention, where the amount of each component is expressed in units of mg/g final composition, and given in both ranges and exemplary quantities (parentheses). The resulting composition is referred to in the studies below as "Formulation Q25C", and is formed as detailed below.

Table 1

Component	Quantity mg/g
<u>Active</u>	
Interferon alpha-2b Drug Substance	.01-5 (0.808)
<u>Excipients and protective agents</u>	
Benzalkonium Chloride 50% Solution	1 – 10 (2)
Butylated Hydroxytoluene	0.1 – 0.5 (0.102)
Cetyl Alcohol	2 – 40 (20.514)
Cholesterol	2 – 40 (20)
Edetate Disodium Dihydrate	0.1 – 0.5 (0.103)
Glycerol Monostearate 40-55, Type 1	5 – 50 (30.771)
Glycine	0.1 – 5 (1)
L-Methionine	0.1 – 5 (1.126)
Methylparaben	0.1– 5 (1.538)
Olive Oil, Super Refined	10 – 70 (51.285)
PEG-40 Castor Oil, Hydrogenated	10 – 70 (51.285)
Sodium phosphate, Dibasic, Heptahydrate	1 – 2 (1.670)
Sodium phosphate, Monobasic, anhydrous	0.25 – 1 (0.480)
Phospholipon 90H	60 – 200 (100)
Propylene Glycol	30 – 100 (69.95)
Propylparaben	0.1 – 1 (0.513)
Purified Water	Q.S. to 1000 (646.846)

Description of the Manufacturing Process for Q25C

Step 1. Preparation of oil-in-water microemulsion: Olive oil, glycerol monostearate 40-55 Type I, cetyl alcohol and butylated hydroxy toluene are melted together at $75^{\circ}\text{C} \pm 5^{\circ}\text{C}$. The aqueous component of the emulsion including purified water, PEG-40 castor oil hydrogenated, benzalkonium chloride 50% solution, methylparaben, propylparaben, L-methionine, edetate disodium dihydrate, and phosphates are heated together in a stainless steel vessel at $75^{\circ}\text{C} \pm 5^{\circ}\text{C}$ while stirring until the ingredients are dissolved. The oil component ($75^{\circ}\text{C} \pm 5^{\circ}\text{C}$) is then added to the aqueous component ($75^{\circ}\text{C} \pm 5^{\circ}\text{C}$) gradually, while mixing to form a coarse emulsion. Coarse emulsion is then homogenized by processing through a Microfluidizer until a homogeneous emulsion is formed. This microemulsion is cooled down to $8^{\circ}\text{C} - 12^{\circ}\text{C}$.

Step 2: Preparation of the Lipid Phase: The Lipid Phase is prepared by melting Phospholipon 90H, cholesterol and butylated hydroxy toluene with propylene glycol in a MMU 10 mixer by heating to about $80-90^{\circ}\text{C}$ while mixing at a slow speed. The mixing and heating of the Lipid Phase ingredients is continued until a clear melt is formed which is then cooled to about 60°C .

Step 3: Preparation of the Aqueous Phase: The required quantity of IFN alpha-2b stock solution is added and mixed gently with a mixture of L-methionine, glycine and purified water.

Step 4: Product Formulation: The Aqueous Phase containing interferon alpha-2b (from Step 3) is added to the System A (from Step 1) in a stainless steel jacketed mixing tank. This mixture is maintained between $8^{\circ}\text{C} - 12^{\circ}\text{C}$ while the mixture is mixed slowly and purged with nitrogen gas. The cooled mixture of System A-Aqueous Phase is rapidly added to the Lipid Phase which is being mixed at high speed in the MMU10 mixer. Mixing proceeds for 10-15 minutes while the temperature of the mixture is maintained about $57-60^{\circ}\text{C}$. The bulk product thus formed is slowly mixed and cooled to $19^{\circ}\text{C} - 25^{\circ}\text{C}$ in a MMU 10 mixer. The product is transferred from the MMU 10 mixer into a 10 L stainless steel storage vessel and purged with nitrogen gas. The bulk product is filled into 1g polypropylene tubes using a Unipac 100 Filler. The tubes are purged with nitrogen and then the required amount of the product is filled into the tubes, which are thermally sealed. The filled tubes of Interferon alpha-2b Cream are

stored at 5°C ± 3°C.

II. Preclinical and clinical studies on efficacy against LSIL

A. Study Rationale

[0049] At present, there is no immediate therapy available for women with HPV presenting with LSIL. Interferon is known to be active against a variety of HPV-induced lesions, particularly cutaneous lesions, such as genital warts. A therapy that could treat early stage cervical HPV infections would provide a significant benefit to and the physical and emotional well-being of many young women.

B. Summary of Pre-Clinical Studies with Q25C

[0050] Toxicology studies conducted in support of the present invention were conducted in compliance with the requirements of "Good Laboratory Practice for Nonclinical Laboratory Studies" and OECD Principles of Good Laboratory Practice. The following three types of toxicology studies were carried out:

[0051] Skin sensitisation of Topical Interferon Alpha-2b Cream in guinea pigs (Buehler Method).

[0052] Repeated dose dermal irritation study of Topical Biphax Interferon Alpha-2b Cream in rabbits.

[0053] Vaginal irritation study of Interferon Alpha-2b Cream in rabbits.

[0054] Apart from the 3 above mentioned toxicology studies the following should be taken into account for the toxicology profile for IFN-alpha-2b composition of the invention: The active drug substance, interferon alpha-2b, is widely considered a safe drug therapy as marketed world-wide by Helix's supplier of drug substance, Schering Plough (Intron A®).

[0055] Schering Plough has already completed extensive toxicology profiling with interferon alpha-2b in multiple species.

[0056] The patent owner performed the clinical trial described herein such that daily and total interferon alpha-2b administration to patients did not exceed published safety limits.

[0057] The components making up the composition are all quality, recognized ingredients.

[0058] The pre-clinical profiling has included two formulations of Interferon alpha-2b Cream designated "Formulation Q25C" whose composition and method of preparation are described above.

B1. Skin sensitization studies

[0059] A 10-day exploratory study was performed in which Formulation Q25C was applied twice daily to sites on shaven skin of the dorsal aspect of New Zealand Albino rabbits at a concentration of 2 MIU interferon alpha-2b per gram of cream (1x the proposed clinical concentration). Test sites were cleaned in between applications using the moistened gauze technique described above to remove any residual cream from previous applications. Study controls included a negative control (saline) and a vehicle control (identical in composition to Formulation Q25C, minus interferon alpha-2b replaced with additional Purified Water).

[0060] The appearance of skin sites was rated and scored for signs of erythema and oedema daily using the standard Draize scoring system. In addition, animals were observed daily for any sign of systemic toxicity. No necropsy assessments were performed at the end of the study.

[0061] Through the course of this exploratory study, findings for erythema were generally good, (Draize scores for redness of generally 2), and only very slight or slight oedema (score of 1-2) was observed. Most notably, skin fissures present on intact surfaces were apparent in one animal only. No signs of systemic toxicity were observed.

C. Vaginal Irritation studies

[0062] Formulation Q25A was administered intravaginally daily for 5 consecutive days/week for 6 weeks at concentrations of 2 MIU and 20 MIU interferon alpha-2b per gram of cream (1x and 10x the proposed clinical concentration). Study controls included a negative control (saline) and a vehicle control minus interferon (alpha-2b replaced with additional Purified Water).

[0063] The appearance of the vaginal opening and perineum was rated for signs of erythema, oedema and vaginal discharge daily. In addition animals were observed daily for any signs of systemic toxicity, and sacrificed at the end of the study to determine any signs of gross pathology.

[0064] The rabbits did not show evidence of systemic toxicity or vaginal irritation based on in-life observations of the vaginal opening and perineum during the study. At necropsy, no gross pathological findings were noted in tissues/organs (including vagina). Based on the histopathology grading, the cream was classified as a minimal irritant.

[0065] Minimal to mild vaginal epithelial hyperplasia, metaplasia and large vacuolation of the epithelium or lamina propria were observed in several animals to whom vehicle control cream was administered and in 1 saline control animal. Hyperplasia and metaplasia may represent minimal to mild adaptive epithelial responses to repeated daily administration of the vehical cream over the 6-week study duration. There was no vaginal epithelial necrosis, erosion or ulceration present in any animals.

Conclusions from Toxicology Studies To-Date

[0066] The above studies support the conclusion that the composition of the present invention, as embodied in Formulation Q25C, is non-sensitizing, and at worst, a mild to moderate irritant for a transient period initially and, thereafter, only mildly irritating, if at all, through the 30-day period studied.

D. Clinical Studies

[0067] The composition of the present invention, as embodied in the Q25C Formulation, was tested for clinical efficacy and side effects in the treatment of LSIL with HPV status, (Low-Grade Squamous Intraepithelial Lesion with human papaloma virus status), where "intraepithelial" means abnormal cells are only present in the surface layer of the cervix. The objective of the study was to determine efficacy and safety of the application of topical Interferon alpha-2b Cream Q25C compared with a second study performed as a control population to describe the natural history of disease progression or regression. The methodology and clinical study, number of subject studies, and the clinical endpoints are presented in Table 2, and the criteria for evaluation, in Table 3.

Table 2: Clinical Trial summary: Low dose interferon alpha cream for the treatment of cytologically confirmed LSIL with HPV status

Investigated product:	IFN002: topical Interferon alpha-2b Cream HPV001: no treatment
Title of studies:	• Protocol Number: IFN 002 - An open study of topical Interferon alpha-2b Cream for the treatment of cytologically confirmed

	<p>LSIL with HPV status (Phase II)</p> <ul style="list-style-type: none"> • Protocol Number: HPV001 - A 3-month prospective study of women presenting with cytologically confirmed LSIL with HPV+ status – a non interventional study 		
Investigator(s):	<p>Principal Investigators:</p> <ul style="list-style-type: none"> • IFN002: Prof. Dr. med. Achim Schneider, Germany • HPV001: Dr. med. Gerd Böhmer, Germany 		
Study centre(s):	<ul style="list-style-type: none"> • IFN002: 3 centers in Germany • HPV001: 1 center in Germany 		
Objectives:	<ul style="list-style-type: none"> • IFN 002: To determine efficacy and safety of the application of topical Interferon alpha-2b Cream • HPV001: To describe the natural history of disease progression or regression 		
Methodology:	<ul style="list-style-type: none"> • IFN 002: Prospective, open labeled study with 6 weeks of treatment and a 6 week follow-up observation period • HPV001: Prospective single cohort study with a 12 week observation period 		
Total number of subjects (planned and analyzed):		IFN002 (treatment)	HPV001 (control)
	Planned for PP	20	20
	Enrolled/Screened*	78	38
	Safety analysis	20	21
	ITT-Analysis	20	21
	PP-Analysis	15	19
Diagnosis and main criteria for inclusion:	<p>Both studies: Women presenting with cytologically confirmed LSIL with HPV+ status</p>		
Kind and duration of treatment:	<ul style="list-style-type: none"> • IFN 002: topical Interferon alpha-2b Cream for 6 weeks • HPV001: no treatment 		
Criteria for evaluation:	<p>Efficacy:</p> <p>Primary endpoint:</p> <ul style="list-style-type: none"> • IFN002: PAP- response-rate, defined as the proportion of patients with resolution of an abnormal Pap smear during 12 weeks after the start of the treatment period (<i>i.e.</i> week 2 or 4 or 6 or 12 = visit V04, V05, V06 and V07) in the Intention to Treat population (ITT) • HPV001: proportion of patients with resolution of an abnormal Pap smear at the end of the 12 weeks observation period. <p>Secondary endpoints:</p> <ul style="list-style-type: none"> • Same as the primary endpoint for Per Protocol population (PP), however • Proportion of patients with reversion of HPV+ Status to negative (qualitative assessment) during 12 weeks after the start of the observation period (ITT and PP) • Proportion of patients with quantitative reduction of HPV viral load during 12 weeks after the start of the observation period (ITT) <p>Safety:</p> <ul style="list-style-type: none"> • Adverse events • Safety laboratory tests • Vital parameters 		

Table 3

<p>Statistical methods:</p>	<p>Efficacy parameters: Inferential statistical analysis of the efficacy parameters was purely explorative, using $\alpha=0.05$ for each test carried out without α- adjustment for multiple testing. The difference in response rates between both groups was determined with the Chi²-test.</p> <p>Safety parameters: All analyses were of descriptive nature. Laboratory parameters were analyzed by means of the asymptotic Mann-Whitney-U-test (between groups differences) and the asymptotic Wilcoxon- test for dependent samples (within group differences). All AEs were coded according to MedDRA and listed completely and separately by study groups. An AE related and a patient related analysis was performed.</p>
<p>Main efficacy results:</p>	<ul style="list-style-type: none"> • Primary endpoint (ITT): 8 out of 20 patients (40.00%) in the treatment- group were responders compared to 3 out of 21 patients (14.29%) in the control- group. However, Pap smear results of two patients of the treatment group worsened after a preliminary PAP- response at earlier visits. Thus, if one considers PAP- response after the 12 week observation period only, 6 out of 20 patients (30.00%) of the treatment group were responders. • PAP- response in the Per Protocol population (PP): In the treatment- group 7 out of 15 patients (46.67%) were responders compared to 3 out of 19 patients (15.79%) in the control- group. If one considers PAP- response after the 12 week observation period only, 6 out of 15 patients (40.00%) of the treatment group were responders. • Proportion of patients with resolution of HPV+ status (ITT and PP) during 12 weeks treatment period, <i>i.e.</i> patients with an occurrence of HPV- at least one time after V03 =start of treatment). ITT: In the treatment- group 3 out of 20 patients (15.00%) were HPV- responders in contrast to 2 out of 21 patients (9.52%) in the control- group. Comment: the HPV- status of one treatment- group patient worsened at V06, but it was negative again at visit V07. PP: In the treatment- group 2 out of 15 patients (13.33%) were HPV- responders and 2 out of 19 patients (10.53%) in the control- group.
<p>Additional efficacy results</p>	<ul style="list-style-type: none"> • Pap- response from a stratified population of patients entering the study as PAP IIId only (<i>i.e.</i>, per "The Bethesda Classification System" of LSIL cytology). A subgroup analysis of the PAP IIId presenting patients revealed a significant difference between treatment groups. 6 of the 14 PAP IIId patients from the ITT- population of study IFN002 were responders compared to no responder in the 14 PAP IIId patients from the PP-population. • Colposcopic diagnosis. The colposcopic diagnosis was statistically significantly better in the treatment group compared to the control group at the time of individual final observation. In study IFN 002, 12 patients (60%) improved towards 'normal' or atypical'. By comparison, in the non-interventional study, only 2 patients (9.52%) improved at the time of individual final observation
<p>Main safety results:</p>	<ul style="list-style-type: none"> • Adverse events: 36 AEs were documented. 34 AEs in the treatment- group: 7 of these onset before start of treatment. Two SAEs were observed in 1 patient of the control group. AE analyses were based on the 27 AEs of the treatment group which started

	<p>after start of treatment ('treatment emergent AEs'); these 27 AEs occurred in 14 of 20 patients (70.00%) of the treatment- group. According to MedDRA- primary terms 3 AEs came from the category 'Metrorrhagia' and 4 from the category 'Headache'; all other AEs- classes occurred only once or twice. 5 SAEs in 3 patients all without any causal relationship related to treatment occurred under study medication (treatment group: pregnancy before start of treatment in 1 patient, accident during swimming with concussion of the brain and compression of the cervical spine in 1 patient; control group: pregnancy with abortion in 1 patient). There were no deaths and no other significant AEs.</p> <ul style="list-style-type: none"> • Laboratory: Urine: No significant change over time was observed with respect to urine-pH- values. In one center, some urine parameters were determined quantitatively: while there was a clear increase of mean erythrocytes, pre-post-changes were small and not significant for this and the other parameters. In some patients qualitative determined leucocytes, nitrate, protein, urobilinogen, bilirubin and/or blood were found in urine. Blood: Significant between group differences were found with respect to hematocrit, MCV, MCHC, thrombocytes and basophils at start and end of the study, not, however, with respect to the mean pre-post- changes. There seems to be a tendency for an increase in leucocytes (however, not significant), lymphocytes [Gpt/l] (significant), monocytes [Gpt/l] (significant) and basophils [Gpt/l] (significant) in the treatment group patients. Significant between group differences were found with respect to creatinine, ASAT and alkaline phosphatase (AP) at start and end of the study, not, however, with respect to the mean pre-post- changes. There was a significant mean decrease with respect to bilirubin in both groups, and a significant mean increase with respect to ALAT in the control group. For all lab parameters addressed in the CRF, the <u>Investigator's assessment</u> (normal, if outside normal range: clinically relevant or clinically irrelevant) was required. Clinically relevance was documented in a rare number of cases only • Physical examination and vital signs: Only in one case from the treatment- group a pathological finding was observed at visit V06 (angina). Within each study group, the vital signs remained nearly constant during the trial within the limits of normal fluctuation and measurement errors. There was a significant difference between groups (U-tests) with respect to diastolic blood pressure and heart rate at visit V01 with higher values in the treatment- group, but no significant difference with respect to the pre-post- differences.
<p>Conclusions:</p>	<p>Overall the treatment arm has a higher response rate than the untreated compare group. Statistic significance using $\alpha=0.05$ is not met for the primary endpoint if compared directly. However, the small sample size and the fact the studies were conducted separately and independently with slightly different colposcopic examination schedules make this type of comparison difficult.</p> <p>A subgroup analysis of the PAP IIIc presenting patients revealed a significant difference between treatment groups. 6 of the 14 PAP IIIc patients from the ITT-population of study IFN002 were responders compared to no responder in the 14 PAP IIIc patients from the PP-population.</p>

	<p>The colposcopic diagnosis was statistically significantly better in the treatment group compared to the control group at the time of individual final observation. In study IFN 002, 12 patients (60%) improved towards 'normal' or atypical'. By comparison, in the non-interventional study, only 2 patients (9.52%) improved at the time of individual final observation.</p> <p>None of the SAEs was related to the study drug and no other significant AEs occurred. The treatment shows an excellent safety profile.</p> <p>A potential clinical benefit and the lack of significant drug related adverse events are positive indications for the drug tested.</p>
--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[0068] Efficacy parameters: Inferential statistical analysis of the efficacy parameters was purely explorative, using $\alpha=0.05$ for each test carried out without α - adjustment for multiple testing. The difference in response rates between both groups was determined with the Chi²-test.

[0069] The main study outcome was based on the Pap- response rate as compared between the two study populations. Pap smear normalization was considered to occur if the patient's Pap smear improved to group II or better from any of Pap smear groups I IW through IIID as per the common European or "Munich Classification" system of LSIL cytology.

[0070] Safety parameters: All analyses were of descriptive nature. Laboratory parameters were analyzed by means of the asymptotic Mann-Whitney-U-test (between groups differences) and the asymptotic Wilcoxon- test for dependent samples (within group differences). All AEs were coded according to MedDRA and listed completely and separately by study groups. An AE related and a patient related analysis was performed.

- Primary endpoint (ITT): 8 out of 20 patients (40.00%) in the treatment- group were responders compared to 3 out of 21 patients (14.29%) in the control- group. However, Pap smear results of two patients of the treatment group worsened after a preliminary PAP- response at earlier visits. Thus, if one considers PAP- response after the 12 weeks observation period only (as by definition in the control group), 6 out of 20 patients (30.00%) of the treatment group were responders.

[0071] PAP- response in the Per Protocol population (PP): In the treatment- group 7 out of 15 patients (46.67%) were responders compared to 3 out of 19

patients (15.79%) in the control- group. If one considers PAP- response after the 12 weeks observation period only

- **Adverse events:** 36 AEs were documented. 34 AEs in the treatment- group: 7 of these onset before start of treatment. Two SAEs were observed in 1 patient of the control group. AE analyses were based on the 27 AEs of the treatment group which started after start of treatment ('treatment emergent AEs'); these 27 AEs occurred in 14 of 20 patients (70.00%) of the treatment- group. According to MedDRA- primary terms 3 AEs came from the category 'Metrorrhagia' and 4 from the category 'Headache'; all other AEs- classes occurred only once or twice. 5 SAEs in 3 patients all without any causal relationship related to treatment occurred under study medication (treatment group: pregnancy before start of treatment in 1 patient, accident during swimming with concussion of the brain and compression of the cervical spine in 1 patient; control group: pregnancy with abortion in 1 patient). There were no deaths and no other significant AEs.
- **Laboratory: Urine:** No significant change over time was observed with respect to urine-pH- values. In one center, some urine parameters were determined quantitatively: while there was a clear increase of mean erythrocytes, pre-post-changes were small and not significant for this and the other parameters. In some patients qualitative determined leucocytes, nitrate, protein, urobilinogen, bilirubin and/or blood were found in urine. **Blood:** Significant between group differences were found with respect to hematocrit, MCV, MCHC, thrombocytes and basophils at start and end of the study, not, however, with respect to the mean pre-post- changes. There seems to be a tendency for an increase in leucocytes (however, not significant), lymphocytes [Gpt/l] (significant), monocytes [Gpt/l] (significant) and basophils [Gpt/l] (significant) in the treatment group patients. Significant between group differences were found with respect to creatinine, ASAT and alkaline phosphatase (AP) at start and end of the study, not, however, with respect to the mean pre-post- changes. There was a significant mean decrease with respect to bilirubin in both groups, and a significant mean increase with respect to ALAT in the control group. For all lab parameters addressed in the CRF, the **Investigator's assessment** (normal, if outside normal range: clinically relevant or clinically irrelevant) was required. Clinically relevance was documented in a rare number of cases only.

[0072] Physical examination and vital signs: Only in one case from the treatment- group a pathological finding was observed at visit V06 (angina). Within each study group, the vital signs remained nearly constant during the trial within the limits of normal fluctuation and measurement errors. There was a significant difference between groups (U-tests) with respect to diastolic blood pressure and heart rate at visit V01 with higher values in the treatment- group, but no significant difference with respect to the pre-post- differences.

[0073] Overall the treatment arm has a higher response rate than the untreated compare group. Statistic significance using $\alpha=0.05$ is not met for the primary endpoint if compared directly. However, the small sample size and the fact the studies were conducted separately and independently with slightly different colposcopic examination schedules make this type of comparison difficult.

[0074] Additional Efficacy Results: A subgroup analysis of the PAP IIIc presenting patients revealed a significant difference between treatment groups. 6 of the 14 PAP IIIc patients from the ITT-population of study IFN002 were responders compared to no responder in the 14 PAP IIIc patients from the PP-population.

[0075] Beyond the PAP- response rate parameter, the colposcopic diagnosis was statistically significantly better in the treatment group compared to the control group at the time of individual final observation. In study IFN 002, 12 patients (60%) improved towards 'normal' or atypical'. By comparison, in the non-interventional study, only 2 patients (9.52%) improved at the time of individual final observation.

[0076] Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.

IT IS CLAIMED:

1. A biphasic lipid vesicle composition for treating cervical dysplasia by intravaginal delivery, comprising a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine.
2. The composition of claim 1, which is in a cream form.
3. The composition of claim 1, which has an interferon alpha-2b specific activity of between 1 and 3 MIU human interferon alpha-2b per gram composition.
4. The composition of claim 3, which contains between 0.01 to 0.5 weight percent L-methionine.
5. The composition of claim 1, wherein at least 30% percent of the interferon-alpha-2B and L-methionine in the composition are present in the entrapped oil-in-water emulsion.
6. A method of treating cervical dysplasia in the subject, comprising administering intravaginally to the subject, at a dose between 1-20 million international units (MIU) of interferon alpha-2b, a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU per gram composition, and between 0.01 to 0.5 weight percent L-methionine, and repeating said administering at least 3 days/week, for a period of at least 4 weeks.
7. The method of claim 6, wherein the suspension administered has a specific activity between 1 and 3 MIU human interferon alpha-2b per gram composition.
8. The method of claim 6, wherein the suspension administered is in

cream form, and is administered at a dose of between 3-7 g per administration.

9. The method of claim 6, wherein the suspension administered contains between 0.01 to 0.5 weight percent L-methionine.

10. The method of claim 6, wherein at least 30% percent of the interferon alpha-2b and L-methionine in the composition administered are present in the entrapped oil-in-water emulsion.

11. The method of claim 6, wherein said administering is repeated at least 3 days/week, for a period of at least 6 weeks.




Fig. 1




Fig. 2A




Fig. 2B




Fig. 3




Fig. 4

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2008/000563

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC: A61K 38/21 (2006.01) , A61K 31/198 (2006.01) , A61K 9/06 (2006.01) , A61K 9/107 (2006.01) , A61K 9/127 (2006.01) According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) IPC: A61K 38/21 (2006.01) , A61K 31/198 (2006.01) , A61K 9/06 (2006.01) , A61K 9/107 (2006.01) , A61K 9/127 (2006.01)</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Database: Delphion, Canadian Patent Database, PubMed, Google, Key words: interferon/IFN, lipid/liposome/biphasic lipid/multilamellar, cervical dysplasia/intraepithelial neoplasia/CIN/ squamous intraepithelial lesion(SIL)/condyloma acuminatum, and mucosal/intravaginal</p>														
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td> US 6656499 B1 (PHARMADERM LABORATORIES, LTD [CA/CA]) 2 December 2003 (02-12-2003) Entire application, particularly column 3, lines 17-22; column 4, lines 60-67; columns 5 and 6; column 19, lines 61-67; column 29, lines 5-35; and claims. </td> <td>1-11</td> </tr> <tr> <td>X</td> <td> WO 95/03787 (UNIVERSITY OF SASKATCHEWAN [CA/CA]) 9 February 1995 (09-02-1995) Entire application, particularly pages 10-11, 24 and 39-49, Figures and claims. </td> <td>1-11</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US 6656499 B1 (PHARMADERM LABORATORIES, LTD [CA/CA]) 2 December 2003 (02-12-2003) Entire application, particularly column 3, lines 17-22; column 4, lines 60-67; columns 5 and 6; column 19, lines 61-67; column 29, lines 5-35; and claims.	1-11	X	WO 95/03787 (UNIVERSITY OF SASKATCHEWAN [CA/CA]) 9 February 1995 (09-02-1995) Entire application, particularly pages 10-11, 24 and 39-49, Figures and claims.	1-11			
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X	US 6656499 B1 (PHARMADERM LABORATORIES, LTD [CA/CA]) 2 December 2003 (02-12-2003) Entire application, particularly column 3, lines 17-22; column 4, lines 60-67; columns 5 and 6; column 19, lines 61-67; column 29, lines 5-35; and claims.	1-11												
X	WO 95/03787 (UNIVERSITY OF SASKATCHEWAN [CA/CA]) 9 February 1995 (09-02-1995) Entire application, particularly pages 10-11, 24 and 39-49, Figures and claims.	1-11												
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.</p> <table border="1"> <tbody> <tr> <td>* Special categories of cited documents :</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </tbody> </table>			* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means		"P" document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family													
"O" document referring to an oral disclosure, use, exhibition or other means														
"P" document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 10 June 2008 (10-06-2008)		Date of mailing of the international search report 18 July 2008 (18-07-2008)												
Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001-819-953-2476		Authorized officer X. Ma 819- 997-4527												

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. Claim Nos. : 6-11

because they relate to subject matter not required to be searched by this Authority, namely :

a method of treatment of human or animal body by surgery or therapy which the International Search Authority is not required to search under Rule 39.1(iv) of PCT. Regardless, this Authority has carried out a search based on the alleged effect or purpose/use of the product defined in the claims.

2. Claim Nos. :

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :

3. Claim Nos. :

because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2008/000563

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 99/11247 A1 (PHARMADERM LABORATORIES [CA/CA]) 11 March 1999 (11-03-1999)</p> <p>Entire application, Abstract, claims.</p>	1-11
Y	<p>STELLATO G., Intralesional recombinant alpha 2b interferon in the treatment of human papillomavirus-associated cervical intraepithelial neoplasia. Sexually Transmitted Diseases. May-June 1992, Vol. 19, No.3, pages 124-126, ISSN: 0148-5717</p> <p>Entire document</p>	1-11
Y	<p>YLISKOSKI M., ET AL: Topical treatment with human leukocyte interferon of HPV 16 infections associated with cervical and vaginal intraepithelial neoplasias. Gynecologic Oncology. March 1990, Vol. 36, No. 3, pages 353-357, ISSN: 0090-8258.</p> <p>Entire document</p>	1-11

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2008/000563

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
—			
US6656499 B1	02-12-2003	AU1262501 A EP1265638 A1 WO0135998 A1	30-05-2001 18-12-2002 25-05-2001
WO9503787 A1	09-02-1995	AT195866T T AU7343894 A CA2168260 A1 DE69425750D D1 DE69425750T T2 DK711148T T3 EP0711148 A1 ES2152324T T3 GR3034777T T3 PT711148T T SI711148T T1 US5853755 A US5993851 A	15-09-2000 28-02-1995 09-02-1995 05-10-2000 26-04-2001 02-01-2001 15-05-1996 01-02-2001 28-02-2001 28-02-2001 28-02-2001 29-12-1998 30-11-1999
WO9911247 A1	11-03-1999	AU735955B B2 AU8968498 A CA2302494 A1 CN1277551 A EP1023054 A1 JP2001514212TT NZ503568 A US5993852 A	19-07-2001 22-03-1999 11-03-1999 20-12-2000 02-08-2000 11-09-2001 30-03-2001 30-11-1999